Addition of azithromycin to maintenance therapy is beneficial in adults with uncontrolled asthma


Clinical question: Does azithromycin decrease the frequency of asthma exacerbations in adults with persistent asthma symptoms despite use of inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA)?

Background: Asthma is a chronic inflammatory airway disease that is highly prevalent worldwide within a subset of people with asthma who have symptoms that are poorly controlled despite ICS and LABA maintenance therapy. Currently, add-on therapy options include monoclonal antibodies, which are cost prohibitive. The need for additional therapeutic options exists. At the same time, macrolide antibiotics are known to have anti-inflammatory, antiviral, and antibacterial effects and have proven to have beneficial effects on asthma symptoms.

Dr. Faye Farber of Duke University Health System, Durham, N.C.

Dr. Faye Farber

Study design: Randomized, double-blind, placebo-controlled trial.

Setting: Multiple sites throughout Australia.

Synopsis: The AMAZES trial enrolled 420 adult patients with symptomatic asthma despite current use of ICS and LABA. Patients were randomly assigned to receive azithromycin 500 mg or placebo three times a week for 48 weeks. Patients who had hearing impairment, prolonged QTc interval, or emphysema were excluded.

Azithromycin reduced the frequency of asthma exacerbations, compared with placebo (1.07 vs. 1.86 exacerbations/patient-year; incidence rate ratio 0.59; 95% confidence interval, 0.47-0.74; P less than .0001). It also significantly improved asthma-related quality of life according to the Asthma Quality of Life Questionnaire (adjusted mean difference, 0.36; 95% CI, 0.21-0.52; P = .001). Diarrhea occurred more commonly in the azithromycin group but did not result in a higher withdrawal rate.

A significant limitation of this study was generalizability, as the median patient age was 60 years and race was not reported. More research is needed to determine the effect of long-term azithromycin use on microbial resistance.

Bottom line: Adding azithromycin to maintenance ICS and LABA therapy in patients with symptomatic asthma decreased the frequency of asthma exacerbations and improved quality of life.

Citation: Gibson PG et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 12;390(10095):659-68.

Dr. Farber is a medical instructor, Duke University Health System.

Recommended Reading

Home noninvasive ventilation reduces COPD readmissions
The Hospitalist
Incidental lung nodules are frequently not mentioned in hospital discharge summary
The Hospitalist
Infections increase risk of idiopathic VTE
The Hospitalist
ARDS incidence is declining. Is it a preventable syndrome?
The Hospitalist
Journal of Hospital Medicine – Nov. 2017
The Hospitalist
Improving the risk assessment of patients with acute pulmonary embolism
The Hospitalist
Pharmacomechanical thrombolysis does not reduce post-thrombotic syndrome risk
The Hospitalist
Acute kidney injury linked with doubled inpatient VTEs
The Hospitalist
Treat sleep apnea with positive airway pressure, but don’t expect it to prevent heart attacks
The Hospitalist
Inpatient antiviral treatment reduces ICU admissions among influenza patients
The Hospitalist
   Comments ()